We invite you to participate in the 24th Transporter- and Barrier – Days taking place in Bad Herrenalb/Black Forest close to Karlsruhe, Germany, from May 26st to May 28th, 2025.
Subjects of this conference are membrane transport proteins in barrier organs, drug transport and drug delivery across biological membranes, screening models such as MCDK, Caco-2 cells, blood brain barrier cells, skin cells, hepatocytes and others as well as phospholipids in drug delivery. Please forward this message also to colleagues in your department. This conference might also be of special interest for PhD students to get in contact with participating colleagues from the pharma industry.
Please register and submit an abstract for poster or oral presentation until Monday, May 15th 2025. Registration fee is 350,- € covering 2 nights with complete room and board (breakfast, lunch, dinner). In case of questions please call +49-6221-548336 or send an email to transportertage@googlemail.com
Herrenalber Transportertage
We thank our sponsors :
Preliminary Program
to be continued
----------------------------------------------------------------------------------------------------------------------------------------------
Previous Topics of this Conference
• Dual targeting immunoliposomes for drug delivery to the brain
• Ox26-immunoliposomes to target the blood-brain-barrier
• Altered protein expression of ABC and SLC transporters in brain microvessels and cortex of familial Alzheimer´s disease models
• Impact of sodium arsenite on ABC transport proteins
• Establishment of a fast and efficient extraction method for lysophosphatidylcholine by dual centrifugation
• Targeted Lipid Nanoparticles for delivery of mRNA into Central Nervous System
• TNFα modulation of secretion and Ca2+ signaling in small intestinal murine organoids
• Slc23a3: the long sought ascorbate release carrier!
• Translational aspects of oxycodone brain delivery via the proton-coupled organic cation (H+/OC) antiporter in rats and pigs
• Comparative analysis of clinically used paclitaxel formulations with a focus on the extent of paclitaxel transport across the CNS and PNS barriers
• The possible role of sodium/proton exchangers in exocrine fluid secretion
• Rational Selection and Design of Combinational Liposomes Using Phytochemicals
• Stabilization of LysoPC-levels in Patients with Cancer
• SLC Transporter: The metabolic gate of Immune cells
• Striatal blood-brain barrier permeability fluctuates perinatally
• Manipulating the microbiota with vancomycin and high-fibre diet affects SCFA/FFA receptor signalling in rat caecum
• A novel fluorescent substrate for P-Glycoprotein-mediated vesicular and cellular transport assays
• Computational Biopharmaceutics: Biopredicitve technologies in the nanomedicine design space
• MemCross: Molecular dynamics simulations of passive permeation and co-permeation"
• Expression of transporters in Alzheimer's disease: does sex matter?".
• Nanoparticles targeting solute carriers to cross the blood-brain barrier
• Targeting of hepatocytes using a virus-mimetic nanocarrier
• Brain regional drug distribution: relevance to Alzheimer’s disease treatment"
• New Concepts of Pathogenesis and Therapy of Colitis Ulcerosa
• OCTN1 and COPD - Is there a role for drug transporters in pulmonary disease
• Recent attempts to surpass the BBB to treat brain disorders
• Nanoparticle-bound doxorubicin for chemo-therapy of glioblastoma: Update on clinical trials
• Anti-HIV and anti-HCV drugs inhibit p-glycoprotein efflux activity in Caco-2 cells and precision-cut rat and human intestinal slices
• Are PLGA-based glutathione-modified nanoparticles sufficient to cross the blood-brain barrier?
• Assessing the interaction of micro-tumors with cellular barriers in a scalable microfluidic in vitro model
• Availability, Affinity and Avidity: Optimising Transcytosis Properties of Central Nervous System Delivery Systems using Computational Approaches
• Bacteria-derived vesicles show low cytotoxicity but inherent antimicrobial activity against model pathogens
• Cell Specific Effects and Mechanisms Mediated by 1, 25-dihydroxyvitamine D3 in the Protection of Alveolar-capillary Barrier
• Cell-free transport protein expression
• Changes of tricellular tight junction proteins in Crohn’s disease
• Coating of PLA-nanoparticles with cyclic, arginine-rich cell penetrating peptides enables oral delivery of liraglutide
• Combinational Nano-formulation for Increasing Therapeutic Efficacy by Targeting ABC Transporters in Cell-based Models
• Development and testing of a CNS-penetrating translationally relevant TRAIl-variant
• Efficiently targeting drug efflux through modulation of p-glycoprotein activity by small molecules: Design, Synthesis biological and computational study.
• Elucidation of possible distinct digoxin-binding sites within the substrate-binding pocket of P-glycoprotein
• Engineered Protein Capsules as drug delivery platform for treatment of CNS diseases
• Establishment and validation of a viable in vitro skin model from different species for the evaluation of cutaneous diseases
• Exploring the role of the constrictions and the central histidine in Formate-nitrate-transporters
• From human induced pluripotent stem cell to barrier-building endothelial cells - Using a realistic model of the blood-brain barrier for the identification of essential nanoparticle characteristics as drug delivery systems
• Functional characterization of human intestinal ABC and SLC transport proteins in overexpression models and ex vivo intestinal tissue segments
• Hypergravity on Brain Blood Barrier opening : benefit or alteration ?
• Imitating Lipoproteins as Drug Delivery System - Apolipoprotein E-modified Lipid Nanoparticles
• Impact of intestinal and renal membrane transporter ABCB1 gene polymorphisms on the pharmacokinetics of digoxin in healthy Caucasian subjects
• In vitro tools to investigate creatine transport inhibition
• Investigation of apical drug transporter activity using ex vivo porcine intestine to facilitate identification of potential drug-drug-interactions at an early state of drug development
• L-type amino acid transporter 1 utilizing prodrugs: promising approach to targeted brain delivery of CNS drugs
• Measurement of intracellular unbound drug concentrations
• Monitoring Penetration of Target Specific Active Ingredients by Using a Depth Profiling Approach
• Monocarboxylate Transporter 8 Expression Profile: Constant Protein Abundance in Barriers of the CNS versus Developmental Decline of Neuronal Expression
• Multidrug resistance protein 4 (MRP4) excretes paracetamol glutathione and cysteine conjugates from liver and kidney
• Novel Developments and Challenges of Blood-Brain Barrier in vitro Models
• Organ-on-a-Chip technology: 3D human blood-brain-barrier, kidney, and gut models for high-throughput barrier and transport measurements
• Peptide conjugation of glycopeptide antibiotics leads to conjugates that overcome all types of resistance P-gp inhibition in human stem-cell derived brain endothelial cells by Group B Streptococcus
• PLGA nanoparticles for oral drug delivery: Influence of polymer end groups and particle size on permeability in the Caco-2 model
• Self-assembled α-tocopherol transfer protein nanoparticles promote vitamin E delivery across an endothelial barrier
• SLC26A9 as an alternative epithelial Cl- channel in muco-obstructive lung diseases
• Species differences of hNTCP and mNtcp in transport characteristics and the inhibitory potential of selected drugs and pesticides
• Suggestions for improved experimental design of small molecule transfer and transport studies with two compartment cell culture models
• The Aη peptide Impairs LRP-1 dependent clearance of Amyloid β at the BBB
• The blood-brain barrier in obesity – tracing leptin through the endothelial cell
• The blood-saliva barrier: Establishment of in vitro models of the human salivary gland and further characterization of isolated colonies.
• The in vitro evaluation of inhibitory potency of anti-HIV and anti-HCV drugs on P-glycoprotein; impact on digoxin intestinal absorption
• The role of LRP1 in stroke therapy with Actilyse
• Transport of glucose-derived ß-carboline alkaloids across the Caco-2 cell monolayer
• Transport of nucleoside-derived antivirals across the rat and human placental barrier: roles of nucleoside and ATP-binding cassette drug efflux transporters